Possibility of adoptive immunotherapy with peripheral blood-derived CD3-CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis c virus activity

Journal of Immunotherapy

Volumn 34, Issue 2, 2011, Pages 129-138

  Doskali, Marlen ^a   Tanaka, Yuka ^a   Ohira, Masahiro ^a   Ishiyama, Kohei ^a   Tashiro, Hirotaka ^a   Chayama, Kazuaki ^a,b   Ohdan, Hideki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Graduate School of Biomedical Science   (Japan)

Author keywords

adoptive immunity; cytotoxicity; hepatitis C virus; hepatocellular carcinoma; peripheral blood mononuclear cells

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; CYTOTOXICITY; EX VIVO STUDY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REPLICON; VIRUS REPLICATION;

ANTIBODIES, NEUTRALIZING; ANTIGENS, CD3; ANTIGENS, CD56; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HEP G2 CELLS; HEPATITIS C; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79953063490     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182048c4e     Document Type: Article

References (35)

1. Brown RS. Hepatitis C and liver transplantation. Nature. 2005;436:973-978.
2. Petrovic LM. Early recurrence of hepatitis C virus infection after liver transplantation. Liver Transpl. 2006;12:S32-S37. (Pubitemid 44742523)
3. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680-687. (Pubitemid 34183974)
4. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002;8:S14-S18. (Pubitemid 35154038)
5. Hirata M, Kita Y, Saito S, et al. Increase in natural killer cell activity following living-related liver transplantation. Transpl Int. 1998;11(suppl 1):S185-S188. (Pubitemid 128683538)
6. Harada N, Shimada M, Okano S, et al. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J Immunol. 2004;173: 6635-6644. (Pubitemid 39541047)
7. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051-3057.
8. Ishiyama K, Ohdan H, Ohira M, et al. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology. 2006;43:362-372.
9. Ohira M, Ishiyama K, Tanaka Y, et al. Adoptive immu-notherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest. 2009;119:3226-3235.
10. Kurokohchi K, Carrington M, Mann DL, et al. Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology. 1996;23:1181-1188. (Pubitemid 26137065)
11. Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol. 2001;75:8516-8523. (Pubitemid 32768956)
12. Yokota T, Sakamoto N, Enomoto N, et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 2003;4:602-608. (Pubitemid 36939952)
13. Tanabe Y, Sakamoto N, Enomoto N, et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis. 2004;189:1129-1139. (Pubitemid 38457235)
14. Strobl H, Riedl E, Scheinecker C, et al. TGF-beta 1 promotes in vitro development of dendritic cells from CD34+ hemo-poietic progenitors. J Immunol. 1996;157:1499-1507. (Pubitemid 126449086)
15. Carlens S, Gilljam M, Remberger M, et al. Ex vivo T lymphocyte expansion for retroviral transduction: influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution. Exp Hematol. 2000;28:1137-1146.
16. Bohnenkamp HR, Noll T. Development of a standardized protocol for reproducible generation of matured monocyte-derived dendritic cells suitable for clinical application. Cyto-technology. 2003;42:121-131. (Pubitemid 38297838)
17. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687-1696. (Pubitemid 24251113)
18. Mehta BA, Schmidt-Wolf IG, Weissman IL, et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood. 1995;86:3493-3499.
19. Carlens S, Gilljam M, Chambers BJ, et al. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol. 2001;62:1092-1098. (Pubitemid 32971386)
20. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immuno-therapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356:802-807.
21. Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother. 2008;31:63-71. (Pubitemid 351619405)
22. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon: relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med. 1986;164:814-825. (Pubitemid 16024836)
23. Ochoa AC, Gromo G, Alter BJ, et al. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol. 1987;138: 2728-2733. (Pubitemid 17051856)
24. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889-897. (Pubitemid 17041979)
25. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science. 1997;276:111-113. (Pubitemid 27161256)
26. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818-821. (Pubitemid 27366733)
27. Vujanovic NL, Nagashima S, Herberman RB, et al. Non-secretory apoptotic killing by human NK cells. J Immunol. 1996;157:1117-1126.
28. Shi M, Fu J, Shi F, et al. Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection. Clin Immunol. 2009;132:43-54.
29. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med. 2002;195:43-49. (Pubitemid 34074495)
30. Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med. 2002;195:35-41. (Pubitemid 34074494)
31. Li Y, Zhang T, Ho C, et al. Natural killer cells inhibit hepatitis C virus expression. J Leukoc Biol. 2004;76:1171-1179. (Pubitemid 39602953)
32. Wang SH, Huang CX, Ye L, et al. Natural killer cells suppress full cycle HCV infection of human hepatocytes. J Viral Hepat. 2008;15:855-864.
33. McFadden G, Mohamed MR, Rahman MM, et al. Cytokine determinants of viral tropism. Nat Rev Immunol. 2009;9:645-655.
34. Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163-189. (Pubitemid 38174573)
35. Young HA, Bream JH. IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr Top Microbiol Immunol. 2007;316:97-117.